-
Something wrong with this record ?
Safety and Outcome of Intravenous Thrombolysis in Stroke Patients on Prophylactic Doses of Low Molecular Weight Heparins at Stroke Onset
C. Cooray, M. Mazya, R. Mikulik, L. Jurak, M. Brozman, P. Ringleb, A. Dixit, D. Toni, N. Ahmed,
Language English Country United States
Document type Journal Article, Multicenter Study, Observational Study, Research Support, Non-U.S. Gov't
NLK
Free Medical Journals
from 1970 to 1 year ago
Open Access Digital Library
from 1970-01-01
Open Access Digital Library
from 1970-01-01
- MeSH
- Anticoagulants administration & dosage MeSH
- Stroke diagnosis drug therapy mortality MeSH
- Heparin, Low-Molecular-Weight administration & dosage MeSH
- Administration, Intravenous MeSH
- Humans MeSH
- Pre-Exposure Prophylaxis methods MeSH
- Aged MeSH
- Thrombolytic Therapy methods mortality trends MeSH
- Treatment Outcome MeSH
- Check Tag
- Humans MeSH
- Male MeSH
- Aged MeSH
- Female MeSH
- Publication type
- Journal Article MeSH
- Multicenter Study MeSH
- Observational Study MeSH
- Research Support, Non-U.S. Gov't MeSH
Background and Purpose- There are limited data on intravenous thrombolysis treatment in patients with ischemic stroke who have received prophylactic doses of low molecular weight heparins (LMWHs). We aimed to evaluate the safety and outcomes of intravenous thrombolysis treatment in stroke patients taking thromboprophylactic doses of LMWH. Methods- We analyzed 109 291patients treated with intravenous thrombolysis, recorded in the Safe Implementation of Treatments in Stroke International Thrombolysis Register between 2003 and 2017 not taking oral anticoagulants or therapeutic doses of heparin at stroke onset. One thousand four hundred eleven patients (1.3%) were on prophylactic LMWH for deep venous thrombosis prevention. Outcome measures were symptomatic intracerebral hemorrhage, parenchymal hematoma, death within 7 days and 3 months, and functional dependency at 3 months. Results- Patients on LMWH were older, had more severe strokes, more prestroke disability, and comorbidities than patients without LMWH. There was no significant increase in adjusted odds ratios (aOR) for symptomatic intracerebral hemorrhage (aOR, 1.02 [95% CI, 0.48-2.17] as per Safe Implementation of Treatments in Stroke -MOST, aOR, 0.95 [0.59-1.53] per ECASS II]), nor for 7-day mortality (aOR, 1.14 [0.82-1.59]), in the prophylactic LMWH group. The LMWH group had a higher aOR for 3-month mortality (aOR, 1.94 [1.49-2.53]) and functional dependency, aOR, 1.44 (1.10-1.90). Propensity score analysis matching patients on baseline characteristics removed differences between groups on all outcomes except 3-month mortality. Conclusions- Intravenous thrombolysis in patients with acute ischemic stroke on treatment with prophylactic doses of LMWH at stroke onset is not associated with an increased risk of symptomatic intracerebral hemorrhage or early death.
Department of Neurology Heidelberg University Hospital Germany
Faculty Hospital Nitra Constantine Philosopher University Slovakia
Neurocentre Regional Hospital Liberec Czech Republic
University of Newcastle upon Tyne and Newcastle upon Tyne Hospitals NHS Foundation Trust
References provided by Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc20006488
- 003
- CZ-PrNML
- 005
- 20220103082720.0
- 007
- ta
- 008
- 200511s2019 xxu f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1161/STROKEAHA.118.024575 $2 doi
- 035 __
- $a (PubMed)30943884
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a xxu
- 100 1_
- $a Cooray, Charith $u From the Department of Clinical Neurosciences, Karolinska Institutet and Department of Neurology Karolinska University Hospital, Stockholm, Sweden (C.C., M.M., N.A.).
- 245 10
- $a Safety and Outcome of Intravenous Thrombolysis in Stroke Patients on Prophylactic Doses of Low Molecular Weight Heparins at Stroke Onset / $c C. Cooray, M. Mazya, R. Mikulik, L. Jurak, M. Brozman, P. Ringleb, A. Dixit, D. Toni, N. Ahmed,
- 520 9_
- $a Background and Purpose- There are limited data on intravenous thrombolysis treatment in patients with ischemic stroke who have received prophylactic doses of low molecular weight heparins (LMWHs). We aimed to evaluate the safety and outcomes of intravenous thrombolysis treatment in stroke patients taking thromboprophylactic doses of LMWH. Methods- We analyzed 109 291patients treated with intravenous thrombolysis, recorded in the Safe Implementation of Treatments in Stroke International Thrombolysis Register between 2003 and 2017 not taking oral anticoagulants or therapeutic doses of heparin at stroke onset. One thousand four hundred eleven patients (1.3%) were on prophylactic LMWH for deep venous thrombosis prevention. Outcome measures were symptomatic intracerebral hemorrhage, parenchymal hematoma, death within 7 days and 3 months, and functional dependency at 3 months. Results- Patients on LMWH were older, had more severe strokes, more prestroke disability, and comorbidities than patients without LMWH. There was no significant increase in adjusted odds ratios (aOR) for symptomatic intracerebral hemorrhage (aOR, 1.02 [95% CI, 0.48-2.17] as per Safe Implementation of Treatments in Stroke -MOST, aOR, 0.95 [0.59-1.53] per ECASS II]), nor for 7-day mortality (aOR, 1.14 [0.82-1.59]), in the prophylactic LMWH group. The LMWH group had a higher aOR for 3-month mortality (aOR, 1.94 [1.49-2.53]) and functional dependency, aOR, 1.44 (1.10-1.90). Propensity score analysis matching patients on baseline characteristics removed differences between groups on all outcomes except 3-month mortality. Conclusions- Intravenous thrombolysis in patients with acute ischemic stroke on treatment with prophylactic doses of LMWH at stroke onset is not associated with an increased risk of symptomatic intracerebral hemorrhage or early death.
- 650 _2
- $a intravenózní podání $7 D061605
- 650 _2
- $a senioři $7 D000368
- 650 _2
- $a antikoagulancia $x aplikace a dávkování $7 D000925
- 650 _2
- $a ženské pohlaví $7 D005260
- 650 _2
- $a heparin nízkomolekulární $x aplikace a dávkování $7 D006495
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a mužské pohlaví $7 D008297
- 650 _2
- $a preexpoziční profylaxe $x metody $7 D065129
- 650 _2
- $a cévní mozková příhoda $x diagnóza $x farmakoterapie $x mortalita $7 D020521
- 650 _2
- $a trombolytická terapie $x metody $x mortalita $x trendy $7 D015912
- 650 _2
- $a výsledek terapie $7 D016896
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a multicentrická studie $7 D016448
- 655 _2
- $a pozorovací studie $7 D064888
- 655 _2
- $a práce podpořená grantem $7 D013485
- 700 1_
- $a Mazya, Michael $u From the Department of Clinical Neurosciences, Karolinska Institutet and Department of Neurology Karolinska University Hospital, Stockholm, Sweden (C.C., M.M., N.A.).
- 700 1_
- $a Mikulik, Robert $u International Clinical Research Center and Neurology Department, St Anne's University Hospital in Brno, Masaryk University, Czech Republic (R.M.).
- 700 1_
- $a Jurák, Lubomír $u Neurocentre, Regional Hospital Liberec, Czech Republic (L.J.). $7 xx0267976
- 700 1_
- $a Brozman, Miroslav $u Faculty Hospital Nitra, Constantine Philosopher University, Slovakia (M.B.).
- 700 1_
- $a Ringleb, Peter $u Department of Neurology, Heidelberg University Hospital, Germany (P.R.).
- 700 1_
- $a Dixit, Anand $u University of Newcastle upon Tyne and Newcastle upon Tyne Hospitals NHS Foundation Trust (A.D.).
- 700 1_
- $a Toni, Danilo $u Emergency Department Stroke Unit, Hospital Policlinico Umberto I, Department of Neurology and Psychiatry, Sapienza University, Rome, Italy (D.T.).
- 700 1_
- $a Ahmed, Niaz $u From the Department of Clinical Neurosciences, Karolinska Institutet and Department of Neurology Karolinska University Hospital, Stockholm, Sweden (C.C., M.M., N.A.).
- 773 0_
- $w MED00010659 $t Stroke $x 1524-4628 $g Roč. 50, č. 5 (2019), s. 1149-1155
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/30943884 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y a $z 0
- 990 __
- $a 20200511 $b ABA008
- 991 __
- $a 20220103082719 $b ABA008
- 999 __
- $a ok $b bmc $g 1525346 $s 1096544
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2019 $b 50 $c 5 $d 1149-1155 $e - $i 1524-4628 $m Stroke $n Stroke $x MED00010659
- LZP __
- $a Pubmed-20200511